loading page

Fatal Temozolomide induced aplastic anemia in a female with Glioblastoma Multiforme ,A case report and literature review
  • Fateen Ata,
  • SAFNA FARSANA AKKAM VEETTIL
Fateen Ata
Hamad Medical Corporation
Author Profile
SAFNA FARSANA AKKAM VEETTIL
Author Profile

Abstract

Temozolomide (TMZ) is a standard of care treatment for Glioblastoma Multiforme (GBM). We report a fatal outcome of a 55 years old female with GBM who developed persistent aplastic anemia (AA) while being treated with TMZ. This case highlights the possibility of a dose-independent and fatal AA secondary to TMZ.

Peer review status:Published

04 Oct 2020Submitted to Clinical Case Reports
08 Oct 2020Submission Checks Completed
08 Oct 2020Assigned to Editor
17 Nov 2020Reviewer(s) Assigned
26 Nov 2020Review(s) Completed, Editorial Evaluation Pending
14 Dec 2020Editorial Decision: Revise Minor
23 Dec 20201st Revision Received
29 Dec 2020Submission Checks Completed
29 Dec 2020Assigned to Editor
29 Dec 2020Review(s) Completed, Editorial Evaluation Pending
11 Jan 2021Editorial Decision: Accept
28 Jan 2021Published in Clinical Case Reports. 10.1002/ccr3.3860